Pfizer

News

AbbVie files Qulipta for chronic migraine prevention

AbbVie has filed for approval of its oral CGRP inhibitor Qulipta for prevention of chronic migraine, seeking to leap ahead of its main rival in the class.

News

Parasitic biting insect on background of epidermis detail. Disgusting carrier of encephalitis, Lyme disease or babesiosis infections. Tick-borne diseases

Pfizer takes stake in French Lyme disease jab partner Valnev...

Pfizer has acquired an 8.1% stake in French vaccines developer Valneva at a cost of €90.5 million (around $95 million) and rejigged the terms of their alliance to develop a shot for Lyme di

Market Access

Six months after authorization, what do we know about Paxlov...

It has now been over six months since the

News

FDA advisors back COVID jabs for very young children

The FDA's vaccines advisors have voted in favour of extending the use of mRNA-based COVID-19 vaccine from Moderna and Pfizer/BioNTech to include children from the ages of six months.

News

Lilly's Olumiant okayed in alopecia, with Pfizer, Concert in...

Eli Lilly and Incyte's Olumiant has secured the first FDA approval for a systemic drug to treat alopecia areata, an autoimmune condition causing patchy hair loss that affects more than 700,

News

Relief for GSK as RSV vaccine clears phase 3 test in adults

GSK will start preparations for regulatory filings of its respiratory syncytial virus (RSV) vaccine straight away, after the shot hit the mark in the much-anticipated AReSVi 006 trial in ad

AbbVie files Qulipta for chronic migraine prevention

Pfizer takes stake in French Lyme disease jab partner Valnev...

Six months after authorization, what do we know about Paxlov...

FDA advisors back COVID jabs for very young children

Lilly's Olumiant okayed in alopecia, with Pfizer, Concert in...

Relief for GSK as RSV vaccine clears phase 3 test in adults

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

Pfizer

Editor's Picks